PCM
PCRX icon

Princeton Capital Management’s Pacira BioSciences PCRX Stock Holding History

Princeton Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,153
Closed -$888K – 96
2023
Q2 		$888K Sell
22,153
-1,350
-6% -$55.8K 0.37% 46
2023
Q1 		$959K Sell
23,503
-773
-3% -$30.8K 0.41% 47
2022
Q4 		$937K Sell
24,276
-1,174
-5% -$57.1K 0.42% 49
2022
Q3 		$1.35M Buy
25,450
+911
+4% +$50.7K 0.59% 38
2022
Q2 		$1.43M Sell
24,539
-367
-1% -$24K 0.55% 43
2022
Q1 		$1.9M Sell
24,906
-335
-1% -$22.3K 0.59% 40
2021
Q4 		$1.52M Buy
25,241
+917
+4% +$50.6K 0.44% 50
2021
Q3 		$1.36M Buy
24,324
+979
+4% +$56.4K 0.43% 51
2021
Q2 		$1.42M Buy
23,345
+834
+4% +$52.8K 0.44% 48
2021
Q1 		$1.58M Buy
22,511
+362
+2% +$25.9K 0.53% 46
2020
Q4 		$1.32M Buy
22,149
+500
+2% +$29.3K 0.47% 49
2020
Q3 		$1.3M Buy
21,649
+901
+4% +$52.4K 0.52% 47
2020
Q2 		$1.09M Buy
20,748
+4,862
+31% +$203K 0.48% 46
2020
Q1 		$663K Sell
15,886
-3,794
-19% -$158K 0.34% 51
2019
Q4 		$931K Sell
19,680
-1,219
-6% -$51.8K 0.42% 46
2019
Q3 		$796K Sell
20,899
-29
-0.1% -$1.16K 0.39% 47
2019
Q2 		$910K Buy
20,928
+1,099
+6% +$46.7K 0.44% 45
2019
Q1 		$755K Sell
19,829
-1,549
-7% -$60.5K 0.38% 47
2018
Q4 		$920K Sell
21,378
-6,390
-23% -$298K 0.54% 39
2018
Q3 		$1.36M Sell
27,768
-571
-2% -$24.7K 0.57% 36
2018
Q2 		$908K Sell
28,339
-210
-0.7% -$7.25K 0.39% 44
2018
Q1 		$889K Sell
28,549
-489
-2% -$17.4K 0.39% 45
2017
Q4 		$1.33M Buy
+29,038
New +$1.15M 0.59% 38

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Princeton Capital Management's PCRX Position: Q3 2023 in Review

Princeton Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 22,153 shares — an estimated $888K sold.

Princeton Capital Management first reported a position in PCRX in Q4 2017 and held it in 23 quarters. The position peaked at $1.9M in Q1 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

  • Princeton Capital Management reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
  • Princeton Capital Management sold 22,153 Pacira BioSciences shares in Q3 2023, an estimated $888K.
  • Princeton Capital Management first reported a position in Pacira BioSciences in Q4 2017 and held it in 23 quarters.
  • Princeton Capital Management's Pacira BioSciences position peaked at $1.9M in Q1 2022.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Princeton Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.